While this study does not justify the cessation of BB, and CVD should continue to be appropriately treated within HER2 positive ABC, the study presents important evidence that the effect of BB may not be the same between cancers or BC subtypes—with the impact potentially being negative within HER2 positive ABC. Here, ERBB2 is linked to breast cancer.